Company: STAA
Filing Date: 2025-11-07
Form Type: DEFA14A
Source: 0001193125-25-271794
Chunk: 6

Company: STAAR SURGICAL CO
Filing Date: 2025-11-07
Form: DEFA14A
Chunk 6
---
 disruption of management’s attention from the Company’s ongoing business operations due to the proposed transaction; (5) the
effect of the announcement of the proposed transaction on the ability of the Company to retain and hire key personnel and maintain relationships with its customers, suppliers and others with whom it does business, or on its operating results and
business generally; (6) the ability of the Company to meet expectations regarding the timing and completion of the transaction; (7) the possibility that no alternative proposals will be received during the
go-shop period, or that any such alternative proposals are not determined by the Company’s board to be superior to the Alcon merger; (8) the outcome of any legal proceedings that may be instituted
against the Company related to the proposed transaction; (9) the possibility that the Company’s stock price may decline significantly if the proposed transaction is not consummated; and (10) other important factors set forth in the
Proxy Statement under the caption “Risk Factors” and the Company’s Annual Report on Form 10-K for the year ended December 27, 2024 under the caption “Risk Factors,” as any
such factors may be updated from time to time in the Company’s other filings with the SEC.

Forward-looking statements speak only as of the date
they are made and, except as may be required under applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

-4-

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| Date: November 7, 2025 |     | STAAR Surgical Company 
 By:                    |     | /s/ Stephen C. Farrell  |
|:-----------------------|:----|:-----------------------|:----|:------------------------|
|                        |     | Name:                  |     | Stephen C. Farrell      |
|                        |     | Title:                 |     | Chief Executive Officer |

Exhibit 2.1

Execution Version

AMENDMENT NO. 1

TO

AGREEMENT AND PLAN OF MERGER

This Amendment No. 1, dated as of November 7, 2025 (this “”), to the Agreement and Plan of Merger, dated
as of August 4, 2025 (the “”), is by and among Alcon Research,